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Abstract
Background: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist
glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The
glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of
NVA237 in patients with moderate-to-severe COPD.
Methods: Patients with COPD with a smoking history of ≥ 10 pack-years, post-bronchodilator forced expiratory
volume in 1 second (FEV1) < 80% and ≥ 30% predicted normal and FEV1/forced vital capacity < 0.70 were enrolled.
Patients were randomized to double-blind treatment with NVA237 50 μg once daily or placebo for 26 weeks with
inhaled/intranasal corticosteroids or H1 antagonists permitted in patients stabilized on them prior to study entry.
The primary outcome measure was trough FEV1 at Week 12.
Results: A total of 822 patients were randomized to NVA237 (n = 552) or placebo (n = 270). Least squares mean
(± standard error) trough FEV1 at Week 12 was significantly higher in patients receiving NVA237 (1.408 ± 0.0105 L),
versus placebo (1.301 ± 0.0137 L; treatment difference 108 ± 14.8 mL, p < 0.001). Significant improvements in
trough FEV1 were apparent at the end of Day 1 and sustained through Week 26. FEV1 was significantly improved
in the NVA237 group versus placebo throughout the 24-hour periods on Day 1 and at Weeks 12 and 26, and at all
other visits and timepoints. Transition dyspnoea index focal scores and St. George’s Respiratory Questionnaire
scores were significantly improved with NVA237 versus placebo at Week 26, with treatment differences of 1.04 (p <
0.001) and-2.81 (p = 0.004), respectively. NVA237 significantly reduced the risk of first moderate/severe COPD
exacerbation by 31% (p = 0.023) and use of rescue medication by 0.46 puffs per day (p = 0.005), versus placebo.
NVA237 was well tolerated and had an acceptable safety profile, with a low frequency of cardiac and typical
antimuscarinic adverse effects.
Conclusions: Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung
function, improvements in dyspnoea, and health-related quality of life, and reduced the risk of exacerbations and
the use of rescue medication.
Trial registration: ClinicalTrials.gov: NCT01005901
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive airflow limitation, results in
breathlessness and reduced exercise capacity, and is a
leading cause of morbidity and mortality [1,2]. The
main goals of pharmacotherapy are to prevent and con-
trol symptoms, reduce the frequency and severity of
exacerbations, improve health status, and increase exer-
cise tolerance [1]. Symptomatic treatment relies to a
large extent on the use of bronchodilators [1], including
long-acting muscarinic antagonists (LAMAs).
Tiotropium is the most frequently used LAMA world-
wide and is an effective bronchodilator. Some patients
taking tiotropium may experience adverse events (AEs)
such as dry mouth, urinary problems and constipation
[3]. Tiotropium has a slow onset of action, with peak
effects on lung function achieved after up to 3 hours
[4]. NVA237 is a once-daily dry-powder formulation of
the LAMA glycopyrronium bromide that is currently in
development for the treatment of COPD. In common
with other LAMAs, the bronchodilatory effects of
NVA237 result from blockade of muscarinic type 1
(M1) and type 3 (M3) receptors, which are involved in
transmission of nerve impulses (M1) and promotion of
contraction (M3) in airway smooth muscle [5].
Among patients with moderate-to-severe COPD,
once-daily NVA237 provides sustained 24-hour bronch-
odilation, has a rapid onset of action and is safe and
well tolerated [6-8]. All evaluated doses of NVA237 (up
to 200 μg) were well tolerated, with doses of 50 or 100
μg once daily having greater efficacy than lower doses
[6-8].
The objective of the Phase III glycopyrronium bro-
mide in COPD airways clinical study 1 (GLOW1) was
to evaluate the efficacy, safety and tolerability of once-
daily NVA237 50 μg, compared with placebo, in patients
with moderate-to-severe COPD.
Methods
Patients
Men and women with moderate-to-severe COPD (as
defined in the 2008 GOLD guidelines) [9] were eligible
for enrolment if they were ≥ 40 years of age, had a
smoking history of ≥ 10 pack-years, post-bronchodilator
forced expiratory volume in 1 second (FEV1)o f<8 0 %
and ≥ 30% of predicted normal value and post-broncho-
dilator FEV1/forced vital capacity (FVC) ratio of < 0.70.
Exclusion criteria included lower respiratory tract infec-
tion within 6 weeks, concomitant pulmonary disease,
history of asthma, lung cancer or long QT syndrome or
QTc > 450 ms (males) or > 470 (females), symptomatic
prostatic hyperplasia, bladder-neck obstruction, moder-
ate/severe renal impairment, urinary retention, narrow-
a n g l eg l a u c o m aa n dh i s t o r yo fa l p h a - 1a n t i t r y p s i n
deficiency. Patients were also excluded if they were par-
ticipating in a supervised pulmonary rehabilitation pro-
gramme, had contraindications for tiotropium or
ipratropium or had experienced adverse reactions to
inhaled anticholinergics.
All patients gave written, informed consent to partici-
pate in the study, which was conducted according to the
principles of Good Clinical Practice and the Declaration
of Helsinki [10]. The study protocol (study
NCT01005901) was reviewed and approved by institu-
tional review boards and ethics committees at participat-
ing centres.
Study design and treatments
In this double-blind, placebo-controlled study, patients
who completed a 7-day pre-screening period and a sub-
sequent 14-day run-in period, were randomized in a 2:1
ratio to 26 weeks of treatment with NVA237 50 μg once
daily or placebo administered via a low-resistance sin-
gle-dose dry-powder inhaler (SDDPI; Breezhaler
®). In
addition to the study treatment, concomitant medica-
tions (inhaled corticosteroids [ICSs], intranasal corticos-
teroids or H1 antagonists) were permitted in patients
who had been stabilized on a recommended and con-
stant dose prior to study entry. Patients were required
to cease taking long-acting bronchodilator therapy
before beginning the run-in period (with a 48-hour
w a s h o u tp e r i o df or long-acting b2-agonist [LABA]/ICS
combinations and a 7-day washout period for tiotro-
pium) and were instructed to use rescue medication.
Patients receiving LABA/ICS combinations were
switched to an equivalent dose of the ICS contained in
the fixed-dose combination product, with rescue medi-
cation available if required. ICS doses had to remain
stable during screening (patients failing screening for
this reason could be re-screened if the ICS dose was sta-
bilized for 1 month). Patients previously treated with a
single-agent ICS continued on their pre-study regimen.
During the randomized treatment period all patients
continued to receive the same ICS regimen that they
received during screening. Patients were provided with a
salbutamol/albuterol inhaler to use as rescue medication
throughout the study.
Efficacy assessments
Efficacy was based on centralized spirometry and
assessed in the full analysis set (FAS), which included all
randomized patients who received at least one dose of
study drug; patients were analyzed according to the
treatment to which they were randomized. Pulmonary
function was assessed in accordance with American
Thoracic Society/European Respiratory Society stan-
dards [11], and the spirometry data was reviewed by a
p u l m o n o l o g i s tt oe n s u r ed a t aq u a l i t y .T or e d u c e
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surements and, whenever possible, the same staff mem-
ber evaluated and coached each patient throughout the
study. The spirometer was calibrated every morning
before taking measurements. The primary outcome
measure was trough FEV1 (mean of the values at 23 h
15 min and 23 h 45 min after dosing) at Week 12. Key
secondary outcome measures were breathlessness on the
transition dyspnoea index (TDI) and health-related qual-
ity of life (HRQoL) according to the St. George’s
Respiratory Questionnaire (SGRQ) at Week 26, while
important secondary outcomes were time to first mod-
erate or severe COPD exacerbation and mean daily res-
cue medication use over 26 weeks.
At Visit 2, all patients were provided with an electro-
nic patient diary to record morning and evening daily
clinical symptoms: cough, wheezing, shortness of breath,
sputum volume and colour, night time awakenings and
rescue medication use. Designated investigator site staff
determined exacerbations by reviewing diary card data
with the patient. COPD exacerbations were defined as
worsening of two or more major symptoms (dyspnoea,
sputum volume or sputum purulence) for at least 2 con-
secutive days or worsening of any one major symptom
together with any minor symptom (colds, fever without
other cause, increased cough, increased wheeze or sore
throat) for at least 2 consecutive days. Exacerbations
were considered to be of moderate severity if they
required treatment with systemic corticosteroids or an
antibiotic and were considered severe if they also
required hospitalization [12,13]. Patients experiencing an
exacerbation were expected to continue in the study if,
in the opinion of the investigator, they could safely be
returned to their pre-exacerbation concomitant medica-
tions. Patients requiring addition of new concomitant
COPD medications after an exacerbation or who were
receiving intra-muscular depot corticosteroids were
withdrawn from the study.
Other efficacy endpoints included trough FEV1 at the
end of Day 1 and at Week 26, serial spirometry on Day
1 and at Weeks 12 and 26, and inspiratory capacity (IC)
on Day 1 and at Weeks 12 and 26. Serial spirometry
was performed in a subset of the FAS, with measure-
ments made over a 12-hour period on Day 1 and during
24 hours at Weeks 12 and 26. Patients practiced the
measurement of IC at screening until reproducible
results could be obtained. Before undertaking an IC
measurement, patients performed normal tidal breathing
and then inhaled to their maximum while receiving ver-
bal encouragement.
Safety assessments
The safety analysis population included all patients who
received at least one dose of study drug, regardless of
whether they were randomized. Patients were analyzed
according to the treatment they received, irrespective of
whether this was the treatment to which they were ran-
domized. Safety was assessed by recording of treatment-
emergent AEs and monitoring of vital signs, electrocar-
diograms and laboratory analyses. AEs were coded using
the Medical Dictionary of Regulatory Activities (Med-
DRA) and summarized by primary system organ class,
preferred term, severity and relationship to study drug.
Statistics
The primary outcome (trough FEV1 at Week 12) was
analyzed using a mixed model, with treatment as a fixed
effect and baseline FEV1, ICS use and FEV1 reversibility
in response to ipratropium asc o v a r i a t e s .T or e f l e c tt h e
randomization scheme, the model also included baseline
smoking status (current/ex-smoker) and region as fixed
effects with centre nested within region as a random
effect. TDI and SGRQ scores and rescue medication use
were analyzed using the same mixed model specified for
the primary analysis, with baseline FEV1 replaced as a
covariate by baseline dyspnoea index, baseline SGRQ
score, and baseline daily rescue medication use,
respectively.
Time to the first moderate or severe COPD exacerba-
tion was analyzed using a Cox regression model, includ-
ing terms for treatment, baseline ICS use, baseline daily
total symptom score, number of moderate or severe
COPD exacerbations in the year prior to screening,
FEV1 reversibility, baseline smoking status and region.
Patients who withdrew from the study and did not
experience a moderate or severe COPD exacerbation
were censored at the date of the last visit or last dose of
study medication (whichever was later). Patients who
completed the study and did not experience a moderate
or severe COPD exacerbation were censored at the
completion visit date. The event rate of moderate or
severe COPD exacerbation was analyzed by a negative
binomial model.
A fixed sequence test procedure was used to handle
multiplicity, with superiorities of NVA237 over placebo
tested sequentially in three families (primary outcome;
key secondary outcomes; important secondary out-
comes) using a hierarchical procedure with Hochberg
step up adjustment and type one error rate controlled at
the 0.05 level within each family. To proceed to the
next family of tests in the hierarchy, tests in the pre-
vious families had to be statistically significant at the
type I error rate of 0.05 after applying the Hochberg
step up adjustment. This fixed sequence testing proce-
dure had no impact on the testing of other secondary
variables.
For the primary efficacy analysis (trough FEV1 at
Week 12), values taken within 6 hours of rescue
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were excluded. The last observation of pre-dose trough
FEV1 was carried forward (LOCF) for missing values.
Similarly, missing values for the assessments of trough
FEV1 at Week 26 were also imputed using the LOCF
(values of pre-dose trough FEV1 were not carried for-
ward for more than 11 weeks).
Results
Patient disposition and baseline characteristics
A total of 822 patients were randomized to treatment
with NVA237 (n = 552) or placebo (n = 270). Approxi-
mately 80% of patients completed the study (Figure 1). A
higher percentage of discontinuations were due to with-
drawal of consent in the NVA237 group (37.3%) than in
the placebo group (24.1%) and a higher percentage were
d u et ou n s a t i s f a c t o r yt h e r a peutic effect in the placebo
group (8.6%) than in the NVA237 group (4.9%) (Figure
1). Baseline demographics and clinical characteristics
were well balanced between treatment groups (Table 1).
Efficacy
Least squares mean (LSM) [± standard error (SE)]
trough FEV1 at Week 12 was significantly higher in
patients receiving NVA237 (1.408 ± 0.0105 L) compared
with placebo (1.301 ± 0.0137 L), with LSM treatment
difference of 108 ± 14.8 mL (p < 0.001; Figure 2).
Trough FEV1 was also significantly higher in the
NVA237 group at the end of Day 1 (1.414 ± 0.0075 L)
and at Week 26 (1.387 ± 0.0112 L), compared with pla-
cebo (1.309 ± 0.0099 L and 1.275 ± 0.0150 L, respec-
tively; both p < 0.001; Figure 2). The treatment
difference was 105 ± 10.9 mL at the end of Day 1 and
113 ± 16.5 mL at Week 26 (both p < 0.001).
On Day 1, LSM (± SE) difference in FEV1 between
NVA237 and placebo was 93 ± 8.5 mL at 5 minutes
and 144 ± 9.7 mL at 15 minutes (both p < 0.001). IC
was also significantly higher in patients in the FAS
population receiving NVA237, at all timepoints on Day
1 and at Weeks 12 and 26 (all p < 0.001; Table 2). The
NVA237-placebo differences for IC by the end of Day
1, Week 12 and Week 26 were 104 mL, 97 mL and
113 mL, respectively (all p < 0.001). Serial spirometry
in a subpopulation of patients revealed significantly
higher values of FEV1 at all timepoints throughout the
24-hour periods on Day 1 and at Weeks 12 and 26 in
patients receiving NVA237 compared with placebo
(Figure 3).
Screened
n = 1324
Randomized
n = 822
Placebo
n = 270
NVA237
n = 552
Completed
Week 26
n = 212 (78.5%)
Completed
Week 26
n = 450 (81.5%)
Discontinued: 102  (18.5%)
• Withdrew consent 38 (37.3%)
• Adverse event 30 (29.4%)
• Administrative problems 21 (20.6%)
• Unsatisfactory therapeutic effect 5 (4.9%)
• Protocol deviation 4 (3.9%)
• Death 2 (2.0%)
• Lost to follow up 1 (1.0%)
• Patient’s inability to use device 1 (1.0%)
Discontinued: 58  (21.5%)
• Withdrew consent 14 (24.1%)
• Adverse event 16 (27.6%)
• Administrative problems 13 (22.4%)
• Unsatisfactory therapeutic effect 5 (8.6%)
• Protocol deviation 3 (5.2%)
• Death 3 (5.2%)
• Lost to follow up 2 (3.4%)
• Patient’s inability to use device 1 (1.7%)
• Patient no longer requires study drug 1 (1.7%)
Figure 1 Patient disposition.
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Page 4 of 13Table 1 Demographic and baseline clinical characteristics
NVA237 50 μg
(n = 550)
Placebo
(n = 267)
Mean (SD) age, years
[range]
63.8 (9.47)
[40.0-91.0]
64.0 (8.96)
[42.0-85.0]
Male gender, n (%) 454 (82.5) 215 (80.5)
Ethnicity, n (%)
Caucasian 346 (62.9) 166 (62.2)
Asian 195 (35.5) 94 (35.2)
Black 3 (0.5) 3 (1.1)
Other 6 (1.1) 4 (1.4)
Mean (SD) body mass index, kg/m
2 25.8 (5.88) 25.6 (5.60)
Severity of COPD, n (%)
Moderate 331 (60.2) 166 (62.2)
Severe 217 (39.5) 99 (37.1)
Very severe 2 (0.4) 2 (0.7)
Mean (SD) duration of COPD, years 5.87 (5.798) 6.49 (6.790)
Baseline COPD exacerbation history*, n (%)
0 exacerbations 433 (78.7) 210 (78.7)
1 exacerbation 90 (16.4) 43 (16.1)
≥ 2 exacerbations 27 (4.9) 14 (5.2)
ICS use at baseline, n (%) 301 (54.7) 136 (50.9)
Smoking history, n (%)
Ex-smoker 370 (67.3) 176 (65.9)
Current Smoker 180 (32.7) 91 (34.1)
Mean (SD) duration of smoking, pack years
Mean (SD) FEV1 (L) pre-bronchodilator
Mean (SD) FEV1 (L) post-bronchodilator
44.9 (28.08)
1.34 (0.45)
1.49 (0.46)
44.6 (24.80)
1.28 (0.43)
1.45 (0.45)
Mean (SD) post-bronchodilator FEV1 percentage predicted 54.75 (13.05) 54.33 (12.84)
Mean (SD) post-bronchodilator FEV1 reversibility, (%) 13.0 (14.21) 15.05 (13.70)
Mean (SD) post-bronchodilator FEV1/FVC, (%) 50.15 (10.26) 49.92 (10.22)
*The number of moderate or severe COPD exacerbations in the year prior to screening
SD: standard deviation
0.8
1.0
1.2
1.4
1.6
Day 1  Week 12  Week 26 
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*
n = 508 n = 248 n = 512 n = 243 n = 461 n = 217
NVA237  Placebo
* *
Figure 2 Trough FEV1 on Day 1 and at Weeks 12 and 26. Data are least squares means ± standard error; *p < 0.001; Treatment differences:
Day 1 = 105 ± 10.9 mL; Week 12 = 108 ± 14.8 mL; Week 26 = 113 ± 16.5 mL.
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0.001) greater TDI focal score at Week 26 (1.84) com-
pared with placebo (0.80), with a treatment difference of
1.04, which exceeded the 1 point treatment difference
considered as clinically important [14] (Table 3, Figure
4a). In addition, patients receiving NVA237 were 1.7-
fold more likely to have a clinically meaningful (≥ 1
point) improvement in TDI focal score compared with
placebo (p = 0.001; Figure 4b). Similarly, at Week 12,
the proportion of patients with a clinically meaningful
improvement in TDI focal score was greater in the
NVA237 group than in the placebo group (p = 0.013).
Patients receiving NVA237 also had a significantly (p =
0.004) lower (better) SGRQ score at Week 26 (39.50)
than those receiving placebo (42.31), with a treatment
difference of -2.81, which was statistically significant but
did not reach the threshold for clinical relevance (≥ 4
point reduction) [15] (Table 3). The percentage of
patients achieving a clinically meaningful improvement
in SGRQ was significantly higher with NVA237 than
with placebo (56.8% versus 46.3%; odds ratio [OR] 1.58,
95% confidence interval [CI] 1.138-2.196; p = 0.006).
NVA237 significantly reduced the risk of COPD
exacerbations in terms of time to first moderate or
severe COPD exacerbation by 31% compared with pla-
cebo (hazard ratio [HR] 0.69, 95% CI 0.500-0.949; p =
0.023; Figure 5). During the 26-week study, 93 of 532
patients (17.5%) in the NVA237 group had one or more
moderate or severe COPD exacerbation, compared with
63 of 260 patients (24.2%) in the placebo group. Further,
there was a significant reduction in the risk of severe
COPD exacerbations leading to hospitalization in the
NVA237 group versus placebo (HR 0.35, 95% CI 0.141-
0.857; p = 0.022). A significant reduction in the percen-
tage of hospitalizations due to COPD exacerbations
(1.7% versus 4.2%, OR 0.34, 95% CI 0.129-0.868; p =
0.024) and a numerical reduction in the rate of moder-
ate or severe exacerbations with NVA237 versus placebo
(0.43 versus 0.59/year; rate ratio 0.72; p = 0.071) was
also observed in the NVA237 group versus placebo. The
use of rescue medication was significantly (p = 0.005)
lower in patients receiving NVA237 than in those
receiving placebo, with a between-group difference of
0.46 puffs/day (Table 3).
Safety
The incidence of AEs was lower in patients receiving
NVA237 (57.5% of patients), compared with placebo
(65.2%), largely due to a higher frequency of COPD
worsening in the placebo group (Table 3). Other AEs,
including those typically associated with anticholinergics
(gastrointestinal disturbances, urinary difficulty, urinary
retention, dry mouth), occurred at low frequencies in
the NVA237 and placebo groups.
Serious adverse events (SAEs) and discontinuations
due to AEs were less frequent in patients receiving
NVA237 than in those receiving placebo (Table 4).
With the exception of serious COPD worsening (less
frequent in the NVA237 group), the majority of indivi-
dual SAEs occurred in similar percentages of patients in
Table 2 Inspiratory capacity on Day 1 and at Weeks 12 and 26 in the FAS population
Inspiratory capacity, L p-value
NVA237 50 μg
(n = 534)
Placebo
(n = 260)
Difference
Day 1
25 min 2.110 ± 0.0148 1.930 ± 0.0194 0.181 ± 0.0212 < 0.001
1 h 55 min 2.166 ± 0.0157 1.978 ± 0.0210 0.189 ± 0.0230 < 0.001
3 h 55 min 2.139 ± 0.0164 1.970 ± 0.0217 0.169 ± 0.0232 < 0.001
23 h 40 min 2.019 ± 0.0168 1.915 ± 0.0222 0.104 ± 0.0239 < 0.001
Week 12
-20 min 1.967 ± 0.0221 1.883 ± 0.0281 0.084 ± 0.0286 0.003
25 min 2.048 ± 0.0216 1.900 ± 0.0274 0.148 ± 0.0278 < 0.001
1 h 55 min 2.103 ± 0.0232 1.923 ± 0.0297 0.180 ± 0.0305 < 0.001
3 h 55 min 2.040 ± 0.0218 1.898 ± 0.0285 0.142 ± 0.0300 < 0.001
23 h 40 min 2.009 ± 0.0212 1.912 ± 0.0282 0.097 ± 0.0296 < 0.001
Week 26
-20 min 1.988 ± 0.0202 1.879 ± 0.0267 0.109 ± 0.0281 < 0.001
25 min 2.055 ± 0.0205 1.905 ± 0.0272 0.150 ± 0.0285 < 0.001
1 h 55 min 2.107 ± 0.0214 1.929 ± 0.0288 0.178 ± 0.0309 < 0.001
3 h 55 min 2.080 ± 0.0206 1.915 ± 0.0283 0.165 ± 0.0304 < 0.001
23 h 40 min 1.997 ± 0.0192 1.884 ± 0.0257 0.113 ± 0.0275 < 0.001
Values are least squares means ± standard errors
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Page 6 of 13the NVA237 and placebo groups. In the NVA237 group
there were three serious atrial fibrillation (AF) events,
two of which occurred in patients with a medical history
of AF (neither was considered related to study
treatment) and one of which occurred in a patient with
a history of myocardial ischaemia but no history of AF
(the event was suspected to be related to study treat-
ment). Two patients receiving NVA237 had serious
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Figure 3 Serial spirometry results on Day 1 (a) and at Weeks 12 (b) and 26 (c). All timepoints are statistically significant (p < 0.01).
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Page 7 of 13congestive heart failure events, one of whom had no
relevant medical history related to the condition and
one of whom had a prior diagnosis of AF. None of the
cases of congestive heart failure events was considered
to be related to study medication.
The number of deaths was low in the NVA237 group
(3 patients, 0.5%) and in the placebo group (3 patients,
1.1%). Two deaths in the NVA237 group occurred dur-
ing the treatment period and were both due to cancer.
The third NVA237 death happened during the 30-day
follow-up period and was due to suicide/depression.
One death in the placebo group was due to a COPD
exacerbation and another was a sudden cardiovascular
death. The cause of death could not be determined in
one placebo recipient, who experienced abdominal pain,
fever and vomiting prior to death. None of the deaths in
either treatment group were suspected to be related to
study treatment by the investigator.
Notable QTcF intervals (> 450 ms for males, > 470 ms
for females) were reported in 4.0% of patients treated
with NVA237 and 1.1% of those receiving placebo
(Table 4). Changes in QTcF interval from baseline of
30-60 ms or > 60 ms occurred in 11.8% of patients
receiving NVA237 and 8.2% of those receiving placebo.
No patient in either treatment group had a QTcF inter-
val > 500 ms.
Discussion
Bronchodilation with LABAs and LAMAs plays a central
role in the management of COPD. LABAs have been
widely used for many years, while the first LAMA (tio-
tropium) became available in Europe in 2002 and in the
USA and Canada in 2004 [16]. More recently, there has
been interest in new LAMAs, such as NVA237 and acli-
dinium, which are currently in development as long-act-
ing bronchodilators for use in the management of
COPD. These new LAMAs would be particularly valu-
able if they could provide bronchodilation at least
equivalent to that of tiotropium, with a low incidence of
troublesome adverse effects. The findings of preclinical
and early clinical studies, which demonstrated a favour-
able efficacy and safety profile of NVA237 [6-8,17], war-
ranted further investigation in Phase III studies.
In the Phase III GLOW1 study, once-daily NVA237
resulted in statistically significant improvement in
trough FEV1 at 12 weeks, with a treatment difference of
108 mL. A steady state for improvement in trough FEV1
versus placebo was achieved at the end of Day 1 and
sustained throughout the study. NVA237 also resulted
in statistically significant increases in TDI score that
exceeded the 1 point difference considered clinically
important [14] and significant improvements in SGRQ
scores, with 56% patients achieving the 4-point thresh-
old regarded as clinically significant improvement [15].
NVA237 also significantly reduced the risk of moderate
or severe COPD exacerbations and was associated with
a numerical reduction in the rate of exacerbations. It
should be noted that a duration of 26 weeks with the
current sample size does not have adequate power to
detect statistically significant differences in the rate of
exacerbations. Additionally, in the population studied, a
majority (> 60%) of the patients had moderate COPD
and < 25% of the patients had a history of COPD
exacerbations prior to screening. This accounts for the
overall low rate of exacerbations observations. It also
makes the improvement in the COPD exacerbations
observed potentially more significant, since it may be
extended to all patients with COPD and not just those
with severe/very severe disease and a history of frequent
exacerbations. Further, the patients with moderate-to-
severe COPD who were enrolled in GLOW1 had a
lower rate of exacerbations prior to enrolment (21%)
Table 3 Dyspnoea, health-related quality of life and use of rescue medication up to Week 26
NVA237 50 μg Placebo
TDI focal score
Least squares mean (± SE) 1.84 ± 0.257 0.80 ± 0.294
Least squares mean difference (± SE) 1.04 ± 0.235
p-value < 0.001
SGRQ score
Baseline mean 46.11 46.34
Least squares mean (± SE) 39.50 ± 0.813 42.31 ± 0.992
Least squares mean difference (± SE) -2.81 ± 0.961
p-value 0.004
Rescue medication use, puffs/day
LSM change from baseline (± SE) -1.21 ± 0.122 -0.75 ± 0.156
Least squares mean difference (± SE) -0.46 ± 0.164
p-value 0.005
TDI: transition dyspnoea index, SGRQ: St. George’s Respiratory Questionnaire
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Page 8 of 13than in the ECLIPSE study, in which 39% of patients
with moderate COPD and 52% of those with severe
COPD had one or more exacerbations during the pre-
vious year [18]. This difference may be due to variations
in the definition of exacerbations (in the GLOW1 study
a pre-defined criteria needed to be met for an event to
be classified as an exacerbation, while the ECLIPSE
study had no such criteria), duration and timing of the
assessment period (e.g. whether it includes the high-risk
winter months), geographic location (since exacerbation
frequency may be affected by weather, climate, and air
pollution), and the frequency of follow-up [19].
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Page 9 of 13The improvements in trough FEV1 versus placebo in
the GLOW1 study are consistent with previous studies
of NVA237 [6,7] and are similar to those seen at Week
12 in randomized, double-blind studies of tiotropium
[20-27]. However, such comparisons require caution due
to differences between the studies (for example, patients
enrolled in the tiotropium studies had more severely
impaired lung function). Several studies of tiotropium
have reported a similar percentage (40-60%) of patients
achieving a clinically significant improvement in SGRQ
scores as in the GLOW1 study [21,22,27-30]. Recent
studies with tiotropium have also shown improvements
in exacerbations, with a significant delay in time to first
exacerbation and time to first hospitalization after an
exacerbation [29,31]. NVA237, in the GLOW1 study,
showed similar results, with a significantly prolonged
time to first moderate/severe exacerbation and severe
exacerbations leading to hospitalization. In these
respects, NVA237 appears to produce effects which are
comparable to tiotropium. However, in other studies tio-
tropium has been shown to reach a steady state for
trough FEV1 only by Day 7 [4,32], compared to Day 1
with NVA237. Thus, NVA237 has a quicker time to
steady state in addition to its faster onset of action [7].
Also, tiotropium has been shown in some studies
[21,28] to result in clinically significant improvements in
TDI score in a lower percentage of patients (45%) than
NVA237 in the current study (62%).
Patients receiving NVA237 in GLOW1 had a numeri-
cally higher frequency of notable QTcF intervals (4.0%
of patients), compared with placebo (1.1%). However, no
patient in either treatment group had a QTcF interval >
500 ms and the overall results from the study indicated
that NVA237 had a good safety profile, with a low fre-
quency of cardiac AEs. Cardiovascular AEs of LAMAs
result from blockade of M2 receptors, which are
thought to modulate pacemaker activity, atrioventricular
conduction and contraction force [33]. The favourable
cardiac safety profile of NVA237 may therefore result
from its high affinity for M3 receptors and low affinity
for M2 receptors, and also from its faster dissociation
from the M2 receptor than from the M3 receptor
[34,35].
Hyperinflation, the main contributor to dyspnoea and
reduced exercise tolerance (dynamic hyperinflation), is
closely associated with IC [36,37]. An increase in IC
after bronchodilator administration signifies a reduction
in hyperinflation, which may translate to a reduction in
dyspnoea and improved exercise tolerance. In the cur-
rent study, IC for NVA237 was higher than baseline
values at all timepoints (25 min, 1 h 55 min, 3 h 55 min
and 23 h 40 min post dose), and was significantly higher
Number at risk
NVA237 490 474 460 447 439 425 411 404 396 393 388 339
Placebo 226 219 211 205 199 1941 89 1841 7 8 171 170 146
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Figure 5 Kaplan-Meier plot of the time to first moderate or severe COPD exacerbation.
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Page 10 of 13than placebo (p < 0.001) in the FAS. It can be hypothe-
sized that the increase in IC with NVA237 allowed for
greater expansion to tidal volume and contributed to
the reduction in dyspnoea. This observation offers an
opportunity to further explore the effect of NVA237 on
dyspnoea and exercise capacity.
Conclusion
T h er e s u l t sf r o mt h eG L O W 1s t u d ys h o w e dt h a to n c e -
daily treatment with NVA237 resulted in significant
improvements in FEV1 and health-related quality of life,
and significant reductions in dyspnoea, risk of exacerba-
tions and rescue medication use. Improvements in FEV1
were rapid, apparent within 5 minutes of dosing on Day
1 of treatment, and were sustained throughout a 24-
hour period from Day 1 up to Week 26. In addition,
NVA237 was generally safe and well tolerated, with a
low incidence of adverse effects typically associated with
antimuscarinic agents.
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Table 4 Frequency of adverse events occurring in ≥ 3% of patients in either group, serious adverse events occurring
in two or more patients in either group, deaths, discontinuations due to adverse events and electrocardiographic
abnormalities
NVA237 50 μg
(n = 550)
Placebo
(n = 267)
Patients with adverse events, n (%) 317 (57.5) 174 (65.2)
COPD worsening 111 (20.2) 73 (27.3)
Nasopharyngitis 28 (5.1) 21 (7.9)
Cough 26 (4.7) 13 (4.9)
Upper respiratory tract infection 23 (4.2) 20 (7.5)
Dyspnoea 18 (3.3) 10 (3.7)
Pyrexia 17 (3.1) 13 (4.9)
Upper respiratory tract infection, bacterial 17 (3.1) 12 (4.5)
Headache 14 (2.5) 10 (3.7)
Patients with serious adverse events*, n (%) 46 (8.4) 24 (9.0)
COPD worsening 9 (1.6) 11 (4.1)
Pneumonia 4 (0.7) 2 (0.7)
Upper respiratory tract infection, bacterial 3 (0.5) 2 (0.7)
Atrial fibrillation 3 (0.5) 0
Dyspnoea 2 (0.4) 0
Respiratory failure 2 (0.4) 0
Cardiac failure congestive 2 (0.4) 0
Myocardial infarction 2 (0.4) 1 (0.4)
Lung neoplasm 2 (0.4) 0
Syncope 2 (0.4) 0
Upper respiratory tract infection 0 2 (0.7)
Myocardial ischaemia 0 2 (0.7)
Deaths**, n (%) 3 (0.5) 3 (1.1)
Discontinuations due to adverse events, n (%) 32 (5.8) 19 (7.1)
Electrocardiographic abnormalities, n (%)
Notable QTcF
† 22 (4.0) 3 (1.1)
QTcF > 500 ms 0 0
Increase from baseline of 30-60 ms 59 (10.7) 21 (7.9)
Increase from baseline of > 60 ms 6 (1.1) 1 (0.4)
* Includes five patients in the NVA237 group that had a serious adverse event that occurred during the 30-day follow-up period. **Includes one patient with a
co-existing history of depression in NVA237 group, who died within 30 days after discontinuing from the study due to suicide/depression.
† > 450 ms for men
and > 470 ms for women
QTcF: QTc interval with Fridericia’s correction
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